Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:AADI

Aadi Bioscience (AADI) Stock Price, News & Analysis

Aadi Bioscience logo
$3.21 -0.04 (-1.23%)
As of 10/23/2026

About Aadi Bioscience Stock (NASDAQ:AADI)

Advanced

Key Stats

Today's Range
$3.08
▼
$3.26
50-Day Range
$2.89
▼
$5.08
52-Week Range
$1.21
▼
$3.81
Volume
222,612 shs
Average Volume
261,100 shs
Market Capitalization
$79.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with genetically defined cancers. The company’s primary product is FYARRO (sirolimus protein-bound particles for injectable suspension), an albumin-bound formulation of sirolimus designed to deliver an mTOR inhibitor to tumors.

FYARRO received approval from the U.S. Food and Drug Administration in 2021 for the treatment of adults with advanced unresectable or metastatic malignant perivascular epithelioid cell tumors, or PEComa, who require systemic therapy. Aadi has also studied the therapy in other advanced solid tumors involving alterations in the TSC1, TSC2, or mTOR genes.

The company was founded as a specialty biopharmaceutical business and has focused primarily on the U.S. market, where FYARRO is marketed through commercial and medical-affairs activities. Aadi Bioscience has been led by founder and Chief Executive Officer Neil Desai, although its corporate strategy and operations have evolved as the company has evaluated development and commercialization opportunities for FYARRO.

AI Generated. May Contain Errors.

Receive AADI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AADI Stock News Headlines

Elon Musk’s Hushed FCC Filing. Dec 8th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel
See More Headlines

AADI Stock Analysis - Frequently Asked Questions

Aadi Bioscience's stock was trading at $2.47 at the beginning of 2026. Since then, AADI shares have increased by 30.0% and is now trading at $3.21.

Aadi Bioscience, Inc. (NASDAQ:AADI) issued its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.37. The business had revenue of $7.24 million for the quarter, compared to analysts' expectations of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative trailing twelve-month return on equity of 71.87%.
Read the conference call transcript
.

Shares of Aadi Bioscience reverse split on Friday, August 27th 2021.The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Pfizer (PFE), iBio (IBIO), Ford Motor (F), NIO (NIO), Nokia (NOK), Advanced Micro Devices (AMD) and Bionano Genomics (BNGO).

Company Calendar

Last Earnings
3/18/2025
Today
10/25/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AADI
CIK
1422142
Fax
N/A
Employees
40
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($2.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.76 million
Net Margins
-246.06%
Pretax Margin
-246.06%
Return on Equity
-71.87%
Return on Assets
-57.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.89
Quick Ratio
4.54

Sales & Book Value

Annual Sales
$25.07 million
Price / Sales
3.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.29 per share
Price / Book
0.75

Miscellaneous

Outstanding Shares
24,697,000
Free Float
15,485,000
Market Cap
$79.28 million
Optionable
No Data
Beta
0.68

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:AADI) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners